Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
GH Research ( (GHRS) ) has issued an update.
GH Research PLC announced its participation in the 38th European College of Neuropsychopharmacology Congress held from October 11-14, 2025, in Amsterdam. The company presented long-term clinical data on its lead product candidate, GH001, which demonstrated safety and efficacy in treating treatment-resistant depression. The data, shared through a symposium presentation and two posters, highlighted GH001’s potential as a rapid-acting antidepressant with a favorable safety profile, reinforcing its promise in addressing the unmet medical need for TRD.
The most recent analyst rating on (GHRS) stock is a Buy with a $40.00 price target. To see the full list of analyst forecasts on GH Research stock, see the GHRS Stock Forecast page.
Spark’s Take on GHRS Stock
According to Spark, TipRanks’ AI Analyst, GHRS is a Neutral.
GH Research’s stock score reflects significant challenges in financial performance, with consistent losses and negative cash flows. The company’s strong equity base and low debt provide some stability. Technical indicators show some short-term momentum, but valuation concerns persist due to the negative P/E ratio and lack of profitability.
To see Spark’s full report on GHRS stock, click here.
More about GH Research
GH Research PLC is a clinical-stage biopharmaceutical company focused on developing innovative treatments for depression, specifically targeting treatment-resistant depression (TRD) with its proprietary mebufotenin therapies.
Average Trading Volume: 303,168
Technical Sentiment Signal: Buy
Current Market Cap: $811.9M
For an in-depth examination of GHRS stock, go to TipRanks’ Overview page.